
MIRM Stock Forecast & Price Target
MIRM Analyst Ratings
Bulls say
Mirum Pharmaceuticals Inc. reported net sales revenue for its product LIVMARLI of $64.1 million in the fourth quarter of 2024, marking an 8.4% growth from the previous quarter and a significant 54.5% increase year-over-year. The company anticipates continued growth from LIVMARLI's indications for Alagille syndrome and progressive familial intrahepatic cholestasis, with a potential for a substantial global market expansion based on positive clinical data. Additionally, Mirum is positioned favorably as a cash-flow positive entity with numerous clinical milestones, including the anticipated launch of its bile acid products for cerebrotendinous xanthomatosis, suggesting further revenue growth opportunities.
Bears say
Mirum Pharmaceuticals Inc faces significant challenges that negatively impact its financial outlook, including the risk of sales growth for its approved products, Livmarli and volixibat, falling well below expectations. The company reported a net loss of $87.9 million for FY2024, primarily driven by high research and development expenses totaling $140.6 million and significant selling, general, and administrative expenses of $202.2 million, raising concerns about future profitability and the potential need for additional capital. Furthermore, uncertainties surrounding regulatory approvals, market competition, and the viability of its late-stage pipeline could hinder commercial success and exacerbate financial strain, potentially leading to shareholder dilution.
This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares